
Lessons learned from the pandemic can advance future biologic drug development and manufacturing.

Lessons learned from the pandemic can advance future biologic drug development and manufacturing.

The importance of characterizing excipients, supply chain security, and the role of novel excipients are explored.

Representatives of industry organizations discuss crucial business, regulatory, science-based issues facing the industry.

How can artificial intelligence and machine learning be used to gather and process real-time manufacturing data?





Laks Pernenkil, a partner for Deloitte’s life sciences consulting business, discusses various findings from Deloitte’s research into the biopharma industry.